3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
9
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Neoplasms
2
Neoplasm Metastasis
1
Interventions
pembrolizumab
34
Specimen Handling
26
Magnetic Resonance Spectroscopy
26
Radiosurgery
25
Biopsy
25
Gemcitabine
22
Nivolumab
21
Paclitaxel
18
Carboplatin
16
Bevacizumab
15
Trastuzumab
14
Everolimus
12
Radiotherapy
11
Irinotecan
11
trastuzumab deruxtecan
10
atezolizumab
10
Erlotinib Hydrochloride
10
Docetaxel
10
Cetuximab
10
Capecitabine
10
Albumin-Bound Paclitaxel
10
130-nm albumin-bound paclitaxel
10
Sorafenib
9
Ipilimumab
9
Cisplatin
9
Taxes
8
Standard of Care
8
Oxaliplatin
8
Drug Therapy
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
abiraterone
×
Tumor-Agnostic
×
Clear all
NCT03295565
2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3
Completed
100 enrolled